Brief: Aridis Receives Agreement From The European Medicines Agency On The Clinical Study Design And A Single Confirmatory Phase 3 Study Of AR-301
17/07/2023 21:25
July 17 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O :
* ARIDIS RECEIVES AGREEMENT FROM THE EUROPEAN MEDICINES
AGENCY
(EMA) ON THE CLINICAL STUDY DESIGN AND A SINGLE CONFIRMATORY
PHASE 3 STUDY OF AR-301
Source text for Eikon: ID:nGNX8xjCRh
Further company coverage: ARDS.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Aridis Pharmaceuticals
See all newsBrief: Aridis Pharmaceuticals Inc - On September 7 Nasdaq Announced That It Would Delist Common Stock Of Co
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
U.S. STOCKS ON THE MOVE-Teladoc Health, NVDIA, Chipotle
U.S. STOCKS ON THE MOVE-Pinterest, Sunrun, Tencent Music